Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II double-blind, placebo-controlled, randomized trial of ExoFlo™ in the treatment of Post-Acute COVID-19 Syndrome

Next Previous
X
Search
Trial Profile

Phase I/II double-blind, placebo-controlled, randomized trial of ExoFlo™ in the treatment of Post-Acute COVID-19 Syndrome

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 27 Jul 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DB-001 (Primary)
  • Indications Post acute COVID 19 syndrome
  • Focus Therapeutic Use
  • Acronyms EIPACS

    • Most Recent Events

    • 27 Jul 2021 Status changed from not stated to planning.
    • 27 Jul 2021 New trial record
    • 20 Jul 2021 According to a Direct Biologics media release, the company has received FDA approval to initiate this trial under an Investigational New Drug (IND) protocol. This trial will be conducted nationally at ambulatory infusion sites in 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top